COVID-19 in children: analysis of the first pandemic peak in England.
epidemiology
virology
Journal
Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
24
06
2020
revised:
20
07
2020
accepted:
23
07
2020
pubmed:
17
8
2020
medline:
15
12
2020
entrez:
16
8
2020
Statut:
ppublish
Résumé
To assess disease trends, testing practices, community surveillance, case-fatality and excess deaths in children as compared with adults during the first pandemic peak in England. England. Children with COVID-19 between January and May 2020. Trends in confirmed COVID-19 cases, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity rates in children compared with adults; community prevalence of SARS-CoV-2 in children with acute respiratory infection (ARI) compared with adults, case-fatality rate in children with confirmed COVID-19 and excess childhood deaths compared with the previous 5 years. Children represented 1.1% (1,408/129,704) of SARS-CoV-2 positive cases between 16 January 2020 and 3 May 2020. In total, 540 305 people were tested for SARS-COV-2 and 129,704 (24.0%) were positive. In children aged <16 years, 35,200 tests were performed and 1408 (4.0%) were positive for SARS-CoV-2, compared to 19.1%-34.9% adults. Childhood cases increased from mid-March and peaked on 11 April before declining. Among 2,961 individuals presenting with ARI in primary care, 351 were children and 10 (2.8%) were positive compared with 9.3%-45.5% in adults. Eight children died and four (case-fatality rate, 0.3%; 95% CI 0.07% to 0.7%) were due to COVID-19. We found no evidence of excess mortality in children. Children accounted for a very small proportion of confirmed cases despite the large numbers of children tested. SARS-CoV-2 positivity was low even in children with ARI. Our findings provide further evidence against the role of children in infection and transmission of SARS-CoV-2.
Identifiants
pubmed: 32796006
pii: archdischild-2020-320042
doi: 10.1136/archdischild-2020-320042
pmc: PMC7431771
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1180-1185Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Infect Dis. 2020 Nov 5;71(8):1943-1946
pubmed: 32301964
Emerg Infect Dis. 2020 Jul;26(7):
pubmed: 32364890
JAMA. 2020 Jun 16;323(23):2427-2429
pubmed: 32432657
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
Laeknabladid. 2020 Mars;106(3):123-129
pubmed: 32124735
Arch Dis Child. 2020 Jul;105(7):618-619
pubmed: 32371442
Br J Gen Pract. 2017 Oct;67(663):440-441
pubmed: 28963401
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Pediatr Infect Dis J. 2020 May;39(5):355-368
pubmed: 32310621
Fam Med Community Health. 2020 Apr;8(2):
pubmed: 32371463
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
IDCases. 2020 May 05;20:e00791
pubmed: 32377507
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Arch Dis Child. 2020 Jul;105(7):704
pubmed: 32376695
Arch Dis Child. 2020 Jul;105(7):613-615
pubmed: 32381519
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
N Engl J Med. 2020 Jul 9;383(2):187-190
pubmed: 32356945
Crit Care Resusc. 2020 Apr 01;22(2):91-94
pubmed: 32227819
JAMA Intern Med. 2020 Sep 1;180(9):1156-1163
pubmed: 32356867
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Vaccine. 2012 Feb 8;30(7):1371-8
pubmed: 22178524
Euro Surveill. 2014 Jan 23;19(3):
pubmed: 24480060
Euro Surveill. 2017 Apr 6;22(14):
pubmed: 28424146